Insider Selling: AtriCure, Inc. (NASDAQ:ATRC) Insider Sells 282 Shares of Stock

AtriCure, Inc. (NASDAQ:ATRCGet Rating) insider Tonya Austin sold 282 shares of the firm’s stock in a transaction that occurred on Friday, April 8th. The stock was sold at an average price of $61.59, for a total transaction of $17,368.38. Following the completion of the transaction, the insider now directly owns 20,824 shares of the company’s stock, valued at approximately $1,282,550.16. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Tonya Austin also recently made the following trade(s):

  • On Friday, March 4th, Tonya Austin sold 1,409 shares of AtriCure stock. The shares were sold at an average price of $67.66, for a total transaction of $95,332.94.
  • On Wednesday, March 2nd, Tonya Austin sold 1,626 shares of AtriCure stock. The shares were sold at an average price of $69.31, for a total transaction of $112,698.06.
  • On Friday, February 11th, Tonya Austin sold 2,490 shares of AtriCure stock. The stock was sold at an average price of $67.97, for a total transaction of $169,245.30.
  • On Friday, January 14th, Tonya Austin sold 2,719 shares of AtriCure stock. The shares were sold at an average price of $66.11, for a total transaction of $179,753.09.

ATRC opened at $58.76 on Thursday. The company has a debt-to-equity ratio of 0.14, a current ratio of 3.47 and a quick ratio of 2.78. The company has a market cap of $2.72 billion, a price-to-earnings ratio of 54.92 and a beta of 1.10. The firm has a 50 day simple moving average of $64.29 and a 200 day simple moving average of $68.41. AtriCure, Inc. has a fifty-two week low of $56.84 and a fifty-two week high of $89.18.

AtriCure (NASDAQ:ATRCGet Rating) last posted its quarterly earnings results on Tuesday, February 15th. The medical device company reported ($0.30) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.26) by ($0.04). AtriCure had a negative return on equity of 11.96% and a net margin of 18.30%. The business had revenue of $73.22 million for the quarter, compared to the consensus estimate of $72.50 million. During the same period last year, the firm earned ($0.18) earnings per share. As a group, analysts expect that AtriCure, Inc. will post -1.09 EPS for the current year.

A number of large investors have recently modified their holdings of ATRC. Millennium Management LLC increased its stake in AtriCure by 196.2% in the fourth quarter. Millennium Management LLC now owns 990,170 shares of the medical device company’s stock valued at $68,847,000 after purchasing an additional 655,861 shares in the last quarter. Alliancebernstein L.P. increased its stake in AtriCure by 18.7% in the fourth quarter. Alliancebernstein L.P. now owns 3,455,856 shares of the medical device company’s stock valued at $240,286,000 after purchasing an additional 544,296 shares in the last quarter. Norges Bank bought a new stake in AtriCure in the fourth quarter valued at approximately $30,737,000. Balyasny Asset Management LLC bought a new stake in AtriCure in the third quarter valued at approximately $21,953,000. Finally, Polar Capital Holdings Plc increased its stake in AtriCure by 65.3% in the third quarter. Polar Capital Holdings Plc now owns 515,910 shares of the medical device company’s stock valued at $35,882,000 after purchasing an additional 203,720 shares in the last quarter. 93.28% of the stock is owned by hedge funds and other institutional investors.

ATRC has been the subject of a number of research analyst reports. Canaccord Genuity Group dropped their target price on shares of AtriCure from $120.00 to $88.00 in a research note on Wednesday, February 16th. Canaccord Genuity Group dropped their target price on shares of AtriCure from $120.00 to $88.00 and set a “buy” rating for the company in a research note on Wednesday, February 16th. BTIG Research reaffirmed a “buy” rating and issued a $94.00 target price on shares of AtriCure in a research note on Monday, March 14th. StockNews.com initiated coverage on shares of AtriCure in a research note on Thursday, March 31st. They issued a “hold” rating for the company. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $79.00 target price on shares of AtriCure in a research note on Thursday, February 24th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, AtriCure presently has an average rating of “Buy” and an average target price of $89.27.

About AtriCure (Get Rating)

AtriCure, Inc develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation.

Further Reading

Insider Buying and Selling by Quarter for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.